Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia

被引：2
|
作者：
Novitzky-Basso, Igor [1 ]
Craddock, Charles [1 ]
机构：
[1] Univ Hosp Birmingham, Ctr Clin Haematol, Birmingham B15 2TH, W Midlands, England
来源：
EUROPEAN JOURNAL OF HAEMATOLOGY | 2011年 / 86卷 / 06期
关键词：
CYTOGENETIC RESPONSES;
D O I：
10.1111/j.1600-0609.2011.01603.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：548 / 549
页数：2
相关论文
共 50 条
  • [1] Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia
    Khoury, Hanna J.
    Goldberg, Stuart L.
    Mauro, Michael J.
    Stone, Richard M.
    Deininger, Michael W.
    Bradley-Garelik, M. Brigid
    Mohamed, Hesham
    Guilhot, Francois
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (06): : 341 - +
  • [2] Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
    Cortes, Jorge E.
    Hochhaus, Andreas
    le Coutre, Philipp D.
    Rosti, Gianantonio
    Pinilla-Ibarz, Javier
    Jabbour, Elias
    Gillis, Kathryn
    Woodman, Richard C.
    Blakesley, Rick E.
    Giles, Francis J.
    Kantarjian, Hagop M.
    Baccarani, Michele
    BLOOD, 2011, 117 (21) : 5600 - 5606
  • [3] Severe pleural effusion associated with nilotinib for chronic myeloid leukaemia: cross-intolerance with tyrosine kinase inhibitors
    Satoh, Kasumi
    Morisawa, Saori
    Okuyama, Manabu
    Nakae, Hajime
    BMJ CASE REPORTS, 2021, 14 (09)
  • [4] Dasatinib/imatinib/nilotinibSkin disorders with cross-intolerance: case report
    Reactions Weekly, 2011, 1371 (1) : 14 - 14
  • [5] MINIMAL CROSS-INTOLERANCE BETWEEN NILOTINIB AND IMATINIB IN PATIENTS WITH IMATINIB-INTOLERANT CHRONIC MYELOGENOUS LEUKAEMIA (CML) IN CHRONIC PHASE (CP) OR ACCELERATED PHASE (AP)
    Hochhaus, A.
    Kantarjian, H. M.
    Baccarani, M.
    Le Coutre, P.
    Haque, A.
    Gallagher, N.
    Cortes, J.
    Giles, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 56 - 57
  • [6] Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukaemia (CMC) in chronic phase (CP) or accelerated phase (AP)
    Cortes, J.
    Jabbour, E.
    Hochhaus, A.
    le Coutre, P.
    Baccarani, M.
    Bhalla, K. N.
    Ossenkoppele, G.
    Gattermann, N.
    Hague, A.
    Gallagher, N.
    Giles, F.
    Hill, S.
    Kantarjian, H. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2008, 141 : 35 - 35
  • [7] Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia
    Ciarcia, Roberto
    Damiano, Sara
    Puzio, Maria Valeria
    Montagnaro, Serena
    Pagnini, Francesco
    Pacilio, Carmen
    Caparrotti, Giuseppe
    Bellan, Cristiana
    Garofano, Tiziana
    Polito, Maria Sole
    Giordano, Antonio
    Florio, Salvatore
    JOURNAL OF CELLULAR PHYSIOLOGY, 2016, 231 (03) : 680 - 687
  • [8] Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib
    Swords, Ronan
    Mahalingam, Devalingam
    Padmanabhan, Swaminathan
    Carew, Jennifer
    Giles, Francis
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2009, 3 : 89 - 101
  • [9] Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation
    Rogers, G.
    Hoyle, M.
    Coon, J. Thompson
    Moxham, T.
    Liu, Z.
    Pitt, M.
    Stein, K.
    HEALTH TECHNOLOGY ASSESSMENT, 2012, 16 (22) : 1 - +
  • [10] Nilotinib against high dose imatinib for salvage therapy of chronic myeloid leukaemia
    Soverini, Simona
    Baccarani, Michele
    Martinelli, Giovanni
    LANCET HAEMATOLOGY, 2016, 3 (12): : E554 - E555
12345